Vanda Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell VNDA and other ETFs, options, and stocks.

About VNDA

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. 

CEO
Mihael Hristos Polymeropoulos
CEOMihael Hristos Polymeropoulos
Employees
533
Employees533
Headquarters
Washington, District of Columbia
HeadquartersWashington, District of Columbia
Founded
2002
Founded2002
Employees
533
Employees533

VNDA Key Statistics

Market cap
433.85M
Market cap433.85M
Price-Earnings ratio
-1.96
Price-Earnings ratio-1.96
Dividend yield
Dividend yield
Average volume
1.13M
Average volume1.13M
High today
$7.50
High today$7.50
Low today
$7.16
Low today$7.16
Open price
$7.29
Open price$7.29
Volume
1.09M
Volume1.09M
52 Week high
$9.94
52 Week high$9.94
52 Week low
$3.81
52 Week low$3.81

Stock Snapshot

As of today, Vanda Pharmaceuticals(VNDA) shares are valued at $7.50. The company's market cap stands at 433.85M, with a P/E ratio of -1.96.

On 2026-04-10, Vanda Pharmaceuticals(VNDA) stock moved within a range of $7.16 to $7.50. With shares now at $7.50, the stock is trading +4.8% above its intraday low and 0.0% below the session's peak.

Trading volume for Vanda Pharmaceuticals(VNDA) stock has reached 1.09M, versus its average volume of 1.13M.

The stock's 52-week range extends from a low of $3.81 to a high of $9.94.

The stock's 52-week range extends from a low of $3.81 to a high of $9.94.

VNDA News

TipRanks 17h
Vanda calls on FDA to remove proposal extending drug review timelines

Vanda Pharmaceuticals (VNDA) highlighted a legislative proposal contained in the FDA’s FY 2027 Congressional Budget Justification.The proposal would eliminate t...

TipRanks 1d
Vanda Pharmaceuticals initiates trial of tradipitant in GLP-1-caused vomiting

Vanda Pharmaceuticals (VNDA) announced the initiation of Thetis, a clinical trial evaluating Nereus – tradipitant – for the prevention of vomiting in patients r...

People also own

Based on the portfolios of people who own VNDA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.